

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AU STAR

奥星

Austar Lifesciences Limited

奥星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

POSITIVE PROFIT ALERT

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2024 and the information currently available to the Board, it is expected that a profit attributable to the owners of the Company in the range of approximately RMB15 million to RMB20 million for the year ended 31 December 2024 will be recorded, as compared with a loss attributable to the owners of the Company of approximately RMB113 million for the year ended 31 December 2023.

The expected turnaround from loss to profit is mainly attributable to the following reasons:

- (1) the absence of a loss of approximately RMB116.5 million, of which approximately RMB80.9 million was attributable to the owners of the Company, as recorded for the year ended 31 December 2023, from H+E Pharma GmbH and S-Tec GmbH, the then indirect non-wholly-owned subsidiaries of the Company;
- (2) an increase in other income of approximately RMB10 million, primarily arising from compensation for disposing of an asset to a local government in Shanghai; and
- (3) the savings in operating expenses of approximately RMB40 million, mainly resulting from the initiatives in the Group’s organizational optimization.

The Group is still in the process of finalising the annual results of the Group for the year ended 31 December 2024. The information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group, including the unaudited consolidated management accounts of the Group for the year ended 31 December 2024, which has not been reviewed by the Company's auditors or the audit committee of the Board and may be subject to adjustments. Details of the Group's financial information and performance will be disclosed when the Group's annual results for the year ended 31 December 2024 are announced, which is expected to be published in late March 2025.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 27 January 2025

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.